Form 4: Acadia CFO Sells 22,000 Shares Under 10b5-1 Plan
Insider Transaction Report
Acadia Pharmaceuticals' CFO, Mark C. Schneyer, sold 22,000 shares of common stock for approximately $554,000 under a pre-arranged trading plan.
Summary
- Mark C. Schneyer, Executive Vice President and Chief Financial Officer of ACADIA PHARMACEUTICALS INC. (ACAD), reported a sale of company common stock.
- On August 18, 2025, Mr. Schneyer disposed of 22,000 shares of ACAD common stock.
- The shares were sold at a weighted average price of $25.1829 per share, totaling approximately $554,039.80.
- The sales were executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Schneyer on May 19, 2025.
- The individual sale prices ranged from $25.06 to $25.28 per share.
- Following this transaction, Mr. Schneyer beneficially owns 40,130 shares of ACAD common stock directly.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While it's an insider sale, the fact that it's under a pre-arranged 10b5-1 plan mitigates any negative implications, suggesting it's for personal financial planning rather than a reaction to company performance.
Positives
- The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on immediate, non-public information, which mitigates concerns about insider selling.
Negatives
- The transaction represents a reduction in direct insider ownership by a key executive, which can sometimes be perceived as a lack of confidence in the company's near-term prospects, even if pre-planned.
Risks
- While executed under a 10b5-1 plan, the sale by a Chief Financial Officer could still be interpreted by some investors as a signal of limited upside potential, potentially leading to negative sentiment.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Management Comments
- The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.
Industry Context
This filing is a routine insider transaction report and does not provide broader industry context or trends. It reflects an individual executive's pre-planned stock sale rather than a company-wide strategic move.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The filing explicitly states that the reported sales were made pursuant to a Rule 10b5-1 trading plan adopted on May 19, 2025. This demonstrates adherence to SEC regulations for insider trading. | 05/19/2025 | The adoption of a 10b5-1 plan enhances transparency and provides an affirmative defense against insider trading allegations, indicating good corporate governance practices regarding executive stock transactions. |
Stakeholder Impact
- Shareholders: May view the reduction in insider ownership with slight caution, though the 10b5-1 plan mitigates concerns about the timing or motivation of the sale.
Key Dates
| Date | Description |
|---|---|
| 05/19/2025 | Date Rule 10b5-1 trading plan was adopted by Mark C. Schneyer. |
| 08/18/2025 | Date of the reported transaction (sale of common stock). |
| 08/19/2025 | Date the Form 4 filing was signed. |
Keywords
ACADIA PHARMACEUTICALS, ACAD, Form 4, Insider Sale, Mark C. Schneyer, CFO, 10b5-1 Plan, Stock Transaction, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.